Original language | English |
---|---|
Pages (from-to) | 281-282 |
Number of pages | 2 |
Journal | Clinical Gastroenterology and Hepatology |
Volume | 20 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2022 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Clinical Gastroenterology and Hepatology, Vol. 20, No. 2, 02.2022, p. 281-282.
Research output: Contribution to journal › Editorial
TY - JOUR
T1 - The Chicago Classification of Pouchitis
T2 - An Important Step Toward a Needed Consensus
AU - Kayal, Maia
AU - Ungaro, Ryan C.
AU - Colombel, Jean Frederic
N1 - Funding Information: Conflicts of interest These authors disclose the following: Ryan C. Ungaro is supported by a National Institutes of Health K23 Career Development Award (K23KD111995-01A1). Jean-Frederic Colombel has received research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; has received payment for lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring Pharmaceuticals, Shire, Takeda, and Tillots; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, lmtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix, and Viela bio; and holds stock options in Intestinal Biotech Development. The other author discloses no conflicts. Funding Information: Conflicts of interest These authors disclose the following: Ryan C. Ungaro is supported by a National Institutes of Health K23 Career Development Award (K23KD111995-01A1). Jean-Frederic Colombel has received research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; has received payment for lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring Pharmaceuticals, Shire, Takeda, and Tillots; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, lmtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG , Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix, and Viela bio; and holds stock options in Intestinal Biotech Development. The other author discloses no conflicts.
PY - 2022/2
Y1 - 2022/2
UR - http://www.scopus.com/inward/record.url?scp=85106353805&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2021.03.025
DO - 10.1016/j.cgh.2021.03.025
M3 - Editorial
C2 - 33753242
AN - SCOPUS:85106353805
SN - 1542-3565
VL - 20
SP - 281
EP - 282
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 2
ER -